Meaning-Centered Intervention for Muslim Patients Who Are Being Treated for Advanced Cancer

NCT ID: NCT04435444

Last Updated: 2025-07-03

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

NA

Total Enrollment

19 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-06-15

Study Completion Date

2026-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will compare the effectiveness of the Masterful supportive care intervention with that of the non-faith-based active control supportive care intervention, which uses the American Cancer Society's patient education materials, for Muslim patients who have advanced cancers.

All 3 sessions may occur within one week or over multiple weeks (nonconsecutively), depending on the participants preference. The participant will have up to 12 weeks from recruitment to complete all sessions and follow up surveys.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Advanced Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

2-group randomized controlled trial (RCT). Using a consecutive patient sampling scheme, we will randomize Muslim patients with stage III or IV cancer.
Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Masterful supportive care

This intervention uses teachings, discussions, and exercises about personal experiences that focus on specific topics related to meaning and cancer. For example, we may discuss what is meaningful in your life, how you identify yourself before and after cancer, and your hopes for the future. The Masterful intervention is available in both English and Arabic, and it will be delivered by a trained bilingual member of the study team. It includes 3 weekly (or at participant's preference) 1-hour sessions with a member of the study team. The sessions for either the treatment or the control arm will take place in-person in a private room at MSKCC or via teleconference, depending on the patients preference. Meeting one-on-one with an interventionist was feasible in our pilot study and will enhance relationship-building between interventionist and patient. Participants will have the option to meet with the interventionist via teleconference in order to reduce in-person contact burden.

Group Type EXPERIMENTAL

Masterful supportive care

Intervention Type OTHER

Three study questionnaires:

Functional Assessment of Cancer Therapy-General\* (FACT-G), Functional Assessment of Chronic Illness Therapy- Spiritual Well-Being\* (FACIT-Sp) Memorial Symptom Assessment Scale Short Form\* (MSAS-SF)

Attention control supportive care

This intervention uses the American Cancer Society's patient education materials. These sessions will include discussions about managing a self-identified current problem in your life. The attention control supportive care intervention is available in both English and Arabic, and it will be delivered by a trained bilingual member of the study team. It includes 3 weekly (or at participant's preference) 1-hour sessions with a member of the study team. The sessions for either the treatment or the control arm will take place in-person in a private room at MSKCC or via teleconference, depending on the patients preference. Meeting one-on-one with an interventionist was feasible in our pilot study and will enhance relationship-building between interventionist and patient. Participants will have the option to meet with the interventionist via teleconference in order to reduce in-person contact burden.

Group Type ACTIVE_COMPARATOR

Attention control supportive care

Intervention Type OTHER

Three study questionnaires:

Functional Assessment of Cancer Therapy-General\* (FACT-G), Functional Assessment of Chronic Illness Therapy- Spiritual Well-Being\* (FACIT-Sp) Memorial Symptom Assessment Scale Short Form\* (MSAS-SF)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Masterful supportive care

Three study questionnaires:

Functional Assessment of Cancer Therapy-General\* (FACT-G), Functional Assessment of Chronic Illness Therapy- Spiritual Well-Being\* (FACIT-Sp) Memorial Symptom Assessment Scale Short Form\* (MSAS-SF)

Intervention Type OTHER

Attention control supportive care

Three study questionnaires:

Functional Assessment of Cancer Therapy-General\* (FACT-G), Functional Assessment of Chronic Illness Therapy- Spiritual Well-Being\* (FACIT-Sp) Memorial Symptom Assessment Scale Short Form\* (MSAS-SF)

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* ≥ 18 years of age
* identify, either as self-report or on the MSKCC EMR, as Muslim
* are in treatment including surveillance, for a confirmed diagnosis of stage III or IV cancer (solid or liquid) as per clinician or pathology report
* have an estimated life expectancy of at least 6 months, as determined by their primary oncologist
* are cognitively intact (oncologist's clinical impression or judgement of study staff)
* able to speak and read English or Arabic (self-reported preference or on the MSKCC EMR system).
* To assess English proficiency, participants will be asked two questions: (1) the Census limited English proficient item "How well do you speak English?" with response options "Not at all, Not well, Well, or Very well" and (2) "What is your preferred language for healthcare?"
* Participants who are eligible for the study and are fluent in English will be identified by the response "Very well" to the 1st question and a response indicating English as the preferred language for healthcare.

Exclusion Criteria

* Major psychiatric illness or cognitive impairment that in the judgment of the study investigators or study staff would preclude study participation
* patients diagnosed with primary brain tumors as per clinician report, as they may have difficulty completing the intervention and answering the questionnaires
* undergoing hematopoietic stem cell transplantation (HSCT) as per clinican report or the EMR
* currently in psychotherapeutic treatment. Symptoms of anxiety and depression are common among patients with stage III or IV cancer. Antidepressants, anxiolytics, and other psychotropic medications do not diminish the effects of psychotherapy; thus we will not exclude patients who are being treated with these medications, as long as they are not in psychotherapy.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

UConn Health

OTHER

Sponsor Role collaborator

Memorial Sloan Kettering Cancer Center

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Francesca Gany, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Memorial Sloan Kettering Cancer Center

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Memorial Sloan Kettering Cancer Center

New York, New York, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Related Links

Access external resources that provide additional context or updates about the study.

http://www.mskcc.org/mskcc/html/44.cfm

Memorial Sloan Kettering Cancer Center

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

20-018

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Awareness Enhancing Interventions
NCT04683510 COMPLETED NA
The Active After Cancer Trial (AACT)
NCT00548236 ACTIVE_NOT_RECRUITING NA